Nci h146

The following cell lines were obtained from the ATCC: A549 (lung adenocarcinoma; CCL‐185), DMS‐53 (small‐cell lung carcinoma; CRL‐2062), IMR‐90 (normal lung; CCL‐186), NCI‐H69 (small‐cell lung carcinoma; HTB‐119), NCI‐H82 (small‐cell lung carcinoma; HTB‐175), NCI‐H146 (small‐cell lung carcinoma; HTB‐173), NCI‐H460 (large cell lung carcinoma; HTB‐177), NCI‐H510A (small‐cell lung carcinoma; HTB‐184), NCI‐H526 (small‐cell lung carcinoma; CRL‐5811), and SHP‐77 (small‐cell lung carcinoma; CRL‐2195). The cells were authenticated and tested for mycoplasma contamination. All cell lines were cultured in the medium and conditions recommended by the supplier and supplemented with 10%FBS, 2 nmol/L l‐glutamine, and penicillin–streptomycin mix (Sigma). For lurbinectedin treatment, cells were seeded and grown to subconfluency before the addition of the drug to the culture medium after having optimized drug concentration (50 nM) and time of lurbinectedin treatment (4 h).

The human SCLC cell line NCI-H69 and the drug-resistant sublines NCI-H69AR, NCI-H446, NCI-H146, and NCI-H1688 were purchased from the American Type Culture Collection (ATCC; Rockville, MD, USA) and maintained in RPMI 1640 medium (HyClone, Logan, UT, USA) with 10 % fetal calf serum (HyClone) in an incubator at 37 °C with 5 % CO₂. The H69AR subline was maintained in a 5 μg/L final concentration of doxorubicin (Jiangshu, China) and transferred to drug-free media for at least 2 weeks before any experiment.

The SCLC cell lines NCI-H82, NCI-H446,
NCI-H211, NCI-H524, NCI-H526, NCI-H146, NCI-H841, and NCI-H209, and
the neuroblastoma cell line SK-N-BE(2) were obtained from American
Type Culture Collection (ATCC, USA). All SCLC cell lines were maintained
in RPMI1640 medium (ThermoFisher Scientific, USA) supplemented with
10% fetal bovine serum (FBS, Hyclone, USA) and antibiotics. SK-N-BE(2)
was maintained in Minimum Essential Medium (MEM, ThermoFisher Scientific,
USA) supplemented with 10% FBS (HyClone, USA) and antibiotics.

The presence of CD63–BCAR4 fusion transcript and expression of BCAR4 were examined in 24 cell lines. Lung cancer cell lines were purchased from Korean cell line bank (KCLB, Seoul, Korea) (NCI-H187, NCI-H417, NCI-H1299, NCI-H596, NCI-H146, SNU-1327, Hcc1195, Hcc1171, NCI-H1703, NCI-H69, Hcc95, Hcc2108, Hcc2279, A427, A549, NCI-H23, NCI-H460 and NCI-H358) and American type culture collection (ATCC, Manassas, VA, USA) (BEAS-2B, NCI-H226, NCI-H2171, NCI-H1395, NCI-H1975 and NCI-H2228). Immortalised human bronchial epithelial cell line BEAS-2B and breast cancer cell line MDA-MB-231 were purchased from ATCC. Each cell line was cultured in the appropriate medium with 10% foetal bovine serum and 1% penicillin–streptomycin or airway epithelial cell basal medium with bronchial epithelial cell growth kit. The authentication of the cell lines was assessed by using short tandem repeat analysis and mycoplasma infection was tested by PCR. Coding regions of the CD63–BCAR4 fusion and BCAR4 (HE601934.1) were cloned into a lentiviral vector with hemagglutinin (HA) tag, CMV promoter and green fluorescent protein (GFP) as a transduction marker. To establish stable cell lines for CD63–BCAR4, BCAR4 and empty vector, the infected cells were sorted by GFP signal intensity.